A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.
Also called NCT02607306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 819 participants
- Sponsor
- Registry
-
NCT02607306
-
- Main results
- Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02607306. Randomized; no masking; primary purpose treatment. Start 2015-11-18 (actual); primary completion 2017-12-15 (actual). Results posted on 2019-07-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
- Acronym
- DUAL™ I Japan
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02607306- Content hash
45737b2a2d2aee6e77e535384535c9d576c916ac807c6adeb92cbafb10a78fe8